NCT07259291 Minto and Eleveld Remifentanil Target Controlled Infusion (TCI) Models: a Clinical Comparison
| NCT ID | NCT07259291 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Padova |
| Condition | Propofol |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-11-25 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2025-11-25 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Remifentanil is commonly used as an opioid during general anesthesia. In recent years, several pharmacokinetic/pharmacodynamic (PK/PD) models for target-controlled infusion (TCI) have been developed, with the Eleveld model being one of the most recent and designed for broad applicability. The aim of this study is to compare the Eleveld TCI model with the routinely used Minto model, in order to evaluate potential differences in the predicted effect-site concentrations (CeR) required to achieve equivalent analgesia levels, as measured by qNOX (CONOX monitor) and the Analgesia Nociception Index (ANI). Post-Tetanic Count (PTC) was also assessed during the maintenance phase to investigate possible differences in nociceptive index responses between the two TCI models.
Eligibility Criteria
Inclusion Criteria: * Undergo general anaesthesia with Targeted Controlled Infusion of Propofol (Eleveld model) and Remifentanil (Minto or Eleveld model) Exclusion Criteria: * Neurological disease * Psychiatric disease
Frequently Asked Questions
Who can join the NCT07259291 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 80 Years, studying Propofol. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07259291 currently recruiting?
Yes, NCT07259291 is actively recruiting participants. Visit ClinicalTrials.gov or contact University of Padova to inquire about joining.
Where is the NCT07259291 trial being conducted?
This trial is being conducted at Treviso, Italy.
Who is sponsoring the NCT07259291 clinical trial?
NCT07259291 is sponsored by University of Padova. The trial plans to enroll 100 participants.